Drug Profile
JJP 1305
Alternative Names: JJP-1305Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator Jeil Pharmaceutical
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Autoimmune-disorders in South Korea
- 28 Apr 2019 No recent reports of development identified for phase-I development in Cancer in South Korea
- 22 Mar 2016 Phase-I clinical trials in Autoimmune disorders in South Korea (unspecified route)